The S & P 500 is down 22% year to date, trading squarely in bear market territory, as concern over high inflation and rising interest rates has pressured the market. Still, there are some parts of the market where the selling may be overdone, creating buying opportunities in stocks that could rally going forward.
5, and analyst expect Ford earning's to grow by 24.5% this year. Pfizer also made the list. The stock is trading at a forward price-to-earnings ratio of 7.9, and analysts see upside of more than 27% on average. Pfizer shares have fallen more than 26% in 2022. Analysts at Cantor Fitzgerald recently reiterated their overweight rating on the stock, noting : "We have also extended our model from 2028E to 2035E and included sales from Biohaven in 2023E and beyond.